Weekly Reports | Jul 10 2026
This story features CENTURIA CAPITAL GROUP, and other companies.
For more info SHARE ANALYSIS: CNI
The company is included in ASX200, ASX300 and ALL-ORDS
A summary of the highlights from Broker Call Extra updates throughout the week past.
Broker Rating Changes (Post Thursday Last Week)
Downgrade
CENTURIA CAPITAL GROUP ((CNI)) Downgrade to Overweight from Buy by Jarden.B/H/S: 0/0/0
Jarden downgrades Centuria Capital to Overweight, with its target price increased to $2.15 from $2.10.
The analyst updates forecasts to reflect a recent $300m equity raising, which lowers pro-forma operating gearing from 12.4% to 3.4%.
These proceeds will fund the acquisition of a 50% interest in the World Square office asset and support the growth of the ResetData business.
The broker notes that the impact of additional securities is broadly offset by debt reduction and incremental co-investment income from properties purchased during the period.
SUNCORP GROUP LIMITED ((SUN)) Neutral by Jarden.B/H/S: 0/0/0
Jarden maintains a Neutral rating for Suncorp Group with its target price reduced to $19.60 from $19.70 following a third consecutive gross written premium downgrade.
The analyst flags risks regarding marginal demand softness in Australia, noting a less supportive environment heading into maiden FY27 guidance.
The broker observes a deliberate margin-over-volume strategy, which may support margin-accretive results even as top-line growth slows.
Earnings support into FY27 is expected to be driven by capital management, potentially including future share buybacks.
TELSTRA GROUP LIMITED ((TLS)) Downgrade to Underweight from Neutral by Jarden.B/H/S: 0/0/0
Jarden downgrades Telstra Group to an Underweight rating from Neutral with the target price reduced to $4.60 as its analysis suggests intensifying long-term structural risks facing the telco’s core mobile network moat.
Emerging technological shifts like satellite direct-to-device capabilities and universal outdoor coverage regulations threaten to compress the firm’s historical mobile pricing premium over peers, the report concludes.
The analyst points out near-term earnings remain secure, framing this asset shift as a distant structural re-rating risk rather than an immediate revenue downgrade threat.
Long-duration cash flows well beyond FY34 carry elevated risk as unique continental coverage benefits gradually equalise across all three major domestic networks.
This network perception erosion prompts the broker to expect terminal multiple compression, likely causing the stock’s required dividend yield to drift higher over the medium term.
| Order | Company | New Rating | Old Rating | Broker | |
|---|---|---|---|---|---|
| Downgrade | |||||
| 1 | CENTURIA CAPITAL GROUP | Buy | Buy | Jarden | |
| 2 | SUNCORP GROUP LIMITED | Neutral | Buy | Jarden | |
| 3 | TELSTRA GROUP LIMITED | Sell | Neutral | Jarden | |
Price Target Changes (Post Thursday Last Week)
| Company | Last Price | Broker | New Target | Old Target | Change | |
|---|---|---|---|---|---|---|
| ALL | Aristocrat Leisure | $62.40 | Jarden | 66.00 | 65.00 | 1.54% |
| AZY | Antipa Minerals | $0.60 | Canaccord Genuity | 1.00 | 1.25 | -20.00% |
| BOE | Boss Energy | $1.26 | Canaccord Genuity | 2.50 | 2.45 | 2.04% |
| BTL | Beetaloo Energy Australia | $0.27 | Research as a Service (RaaS) | 0.95 | 0.94 | 1.06% |
| CGF | Challenger | $10.50 | Jarden | 9.80 | 9.20 | 6.52% |
| CKF | Collins Foods | $7.97 | Jarden | 10.00 | 11.80 | -15.25% |
| CNI | Centuria Capital | $1.80 | Jarden | 2.15 | 1.95 | 10.26% |
| GHM | Golden Horse Minerals | $0.43 | Shaw and Partners | 1.25 | 1.50 | -16.67% |
| GMD | Genesis Minerals | $5.46 | Canaccord Genuity | 8.75 | 9.60 | -8.85% |
| GQG | GQG Partners | $1.44 | Jarden | 1.65 | 1.75 | -5.71% |
| ILA | Island Pharmaceuticals | $0.45 | Research as a Service (RaaS) | 1.60 | 1.24 | 29.03% |
| IMB | Intelligent Monitoring | $0.63 | Canaccord Genuity | 1.25 | 1.05 | 19.05% |
| Moelis | 1.19 | 0.84 | 41.67% | |||
| MYX | Mayne Pharma | $2.84 | Canaccord Genuity | 3.83 | 6.10 | -37.21% |
| NWL | Netwealth Group | $23.35 | Canaccord Genuity | 28.65 | 28.35 | 1.06% |
| Jarden | 25.00 | 25.70 | -2.72% | |||
| OCL | Objective Corp | $6.80 | Moelis | 14.94 | 18.31 | -18.41% |
| Shaw and Partners | 10.80 | 22.10 | -51.13% | |||
| PXA | Pexa Group | $8.13 | Jarden | 9.20 | 9.85 | -6.60% |
| SGM | Sims | $25.07 | Jarden | 27.50 | 30.50 | -9.84% |
| SNZ | Summerset Group | $7.34 | Jarden | N/A | 10.52 | -100.00% |
| SUN | Suncorp Group | $18.90 | Jarden | 19.60 | 19.10 | 2.62% |
| SVR | Solvar | $1.54 | Canaccord Genuity | 1.80 | 2.00 | -10.00% |
| SYL | Symal Group | $2.70 | Jarden | 3.45 | 3.05 | 13.11% |
| TLS | Telstra Group | $4.98 | Jarden | 4.60 | 5.05 | -8.91% |
| WAF | West African Resources | $2.73 | Canaccord Genuity | 5.85 | 7.00 | -16.43% |
| Company | Last Price | Broker | New Target | Old Target | Change | |
More Highlights
AKA AUREKA LIMITED
Gold & Silver – Overnight Price: $0.08
Research as a Service (RaaS) rates ((AKA)) as No Rating (-1) –
Research as a Service (RaaS) highlights junior gold exploration company Aureka’s expanding Victorian gold portfolio. The company’s Irvine resource has increased by 94koz to 398koz, lifting the global resource to 455koz.
The report notes ongoing drilling at Irvine and Comstock, where a prospecting licence application and resource infill program could support a small-scale underground mining operation within 12-24 months.
Following a site visit, the analyst believes Comstock’s proposed mining and toll-treatment strategy appears technically and economically feasible.
Aureka held approximately $3.7m in cash at 31 March, which is expected to fund exploration activities through 2026.
Research as a Service does not carry any ratings or targets. Investors can draw conclusions from valuations and commentary.
This report was published on July 8, 2026.
Current Price is $0.08. Target price not assessed.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ALL ARISTOCRAT LEISURE LIMITED
Gaming – Overnight Price: $62.05
Jarden rates ((ALL)) as Buy (1) –
Jarden maintains a Buy rating for Aristocrat Leisure with its target price increased to $66.00 from $65.00 following a recent investor briefing.
The analyst frames the company’s equity story around its durable, defensive land-based gaming segment despite recent management commentary regarding the complexity of scaling the interactive division.
First pillar bridge targets for fiscal 2029 are adjusted to $892m, which remains slightly below the company’s goal.
The broker notes management’s successful progress on growth initiatives and reiterates its positive outlook on the core business.
Valuation is driven by lower risk-free rates and model roll-forwards.
This report was published on July 3, 2026.
Target price is $66.00 Current Price is $62.05 Difference: $3.95
If ALL meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $64.61, suggesting upside of 4.1%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 256.1, implying annual growth of 11.7%.
Current consensus DPS estimate is 98.9, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 24.2.
Forecast for FY27:
Current consensus EPS estimate is 287.2, implying annual growth of 12.1%.
Current consensus DPS estimate is 109.6, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 21.6.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BTL BEETALOO ENERGY AUSTRALIA LIMITED
Energy – Overnight Price: $0.26
Canaccord Genuity rates ((BTL)) as Speculative Buy (1) –
Canaccord Genuity maintains a Speculative Buy rating for Beetaloo Energy Australia with a $0.45 target price following successful flow back results from the reopened Carpentaria-5H production well.
Initial operations have tracked a peak flow exceeding 14TJ/d before settling down to establish a highly encouraging intermediate production profile.
The analyst notes management is purposefully running restricted choke settings to optimise long-term fracture conductivity and extend well longevity ahead of final pilot plant connection.
First corporate gas sales remain firmly on schedule for completion by the end of 2026 under a 10-year binding agreement with the local government.
Long-term commercial development economics are expected to see material improvements following a strategic funding commitment to build the basin’s first regional frac sand mining operation.
This report was published on July 5, 2026.
Target price is $0.45 Current Price is $0.26 Difference: $0.19
If BTL meets the Canaccord Genuity target it will return approximately 73% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GHM GOLDEN HORSE MINERALS LIMITED
Gold & Silver – Overnight Price: $0.47
Shaw and Partners rates ((GHM)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Golden Horse Minerals with its target price decreased to $1.25 following strong infill drill results from the Hopes Hill project.
Drilling has successfully intersected multiple high-grade targets across three distinct zones within a 3km mineralised corridor.
The latest standout intercept returned 8m at 9.15g/t gold from the southern zone, while new data out of the main pit confirmed parallel hanging wall and footwall lode structures.
Work on an inaugural JORC mineral resource estimate will commence soon, supported by nearly 100km of cumulative drilling since the start of 2025.
The reduction to the final valuation reflects broader adjustments to the broker’s underlying commodity price assumptions, though the analyst suggests the company is building an inventory profile well beyond current market capitalisation levels.
This report was published on July 3, 2026.
Target price is $1.25 Current Price is $0.47 Difference: $0.78
If GHM meets the Shaw and Partners target it will return approximately 166% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 23.50.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 31.33.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GMD GENESIS MINERALS LIMITED
Gold & Silver – Overnight Price: $6.29
Moelis rates ((GMD)) as Buy (1) –
Moelis maintains a Buy rating for Genesis Minerals with a $8.50 target price following a “strong” fourth-quarter preliminary production update.
Production of 70.8koz gold for the quarter pushed total FY26 output to 285.4koz, keeping the result squarely within the company’s annual guidance range.
Strong underlying cash generation of $258m was achieved during the period, successfully absorbing cost pressures from diesel, contractor transitions, and third-party ore purchases.
Operational momentum is building as mining commences at Tower Hill and the Jupiter project transitions to sourcing 100% owned ore for the Laverton processing hub.
The analyst highlights the September 2026 strategy update as a critical catalyst for defining the production and capital pathway towards the company’s ASPIRE 500 growth ambition.
This report was published on July 5, 2026.
Target price is $8.50 Current Price is $6.29 Difference: $2.21
If GMD meets the Moelis target it will return approximately 35% (excluding dividends, fees and charges).
Current consensus price target is $9.29, suggesting upside of 58.0%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 50.0, implying annual growth of 146.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.8.
Forecast for FY27:
Current consensus EPS estimate is 59.7, implying annual growth of 19.4%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 9.8.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ILA ISLAND PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.44
Research as a Service (RaaS) rates ((ILA)) as No Rating (-1) –
Research as a Service (RaaS) believes Island Pharmaceuticals has enhanced the commercial potential of its Galidesivir drug. This follows the securing of approvals for compassionate use during the Bundibugyo Ebola outbreak in Africa.
The analyst expects the program to generate prospective human efficacy, safety and virology data across filoviruses, complementing the company’s Marburg virus development under the FDA’s Animal Rule pathway.
The Uganda Government is fully funding the program with support from the World Health Organisation, providing a non-dilutive opportunity to expand Galidesivir’s clinical dataset, the analyst explains.
Research as a Service raises its probability of success to 65% from 60% and increases its risk-adjusted valuation to $1.60 a share from $1.24.
Research as a Service research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on July 8, 2026.
Target price is $1.60 Current Price is $0.44 Difference: $1.16
If ILA meets the Research as a Service (RaaS) target it will return approximately 264% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.77 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 24.86.
Forecast for FY27:
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 4.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 9.36.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SNT SYNTARA LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.02
Canaccord Genuity rates ((SNT)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Syntara with a $0.15 target price following early positive clinical trial data from its SNT-4728 program.
The Phase IIa trial, assessing the dual inhibitor in isolated REM sleep behaviour disorder, demonstrated a statistically significant reduction in neuroinflammation in the putamen after 12 weeks of treatment.
The analyst notes this early safety and efficacy readout provides highly encouraging upside optionality, potentially supporting future asset-partnering discussions.
The underlying valuation remains anchored by the primary amsulostat blood cancer franchise, which targets myelofibrosis and myelodysplastic syndromes.
Pipeline momentum is expected to build into the second half of 2026 with upcoming clinical trials in high-risk hematology indications and pancreatic cancer.
This report was published on July 8, 2026.
Target price is $0.15 Current Price is $0.02 Difference: $0.127
If SNT meets the Canaccord Genuity target it will return approximately 552% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $16.88
Canaccord Genuity rates ((TLX)) as Buy (1) –
Canaccord Genuity maintains a Buy rating for Telix Pharmaceuticals with a $30.00 target price following FDA alignment on the ProstACT GLOBAL trial protocol.
The regulatory agency agreed to proceed with the GLOBAL-2 study while preserving docetaxel as a standard-of-care option, giving the TLX591 asset unusual flexibility across global treatment consensuses.
The analyst views the trial design as highly powerful because it represents the only live phase 3 radioligand therapy study in metastatic castration-resistant prostate cancer with a chance to hit an overall survival endpoint.
Assuming equivalent efficacy to rival treatments, the suggestion is TLX591 can capture significant market share due to superior revenue intensity for treating centres.
Separately, the OPTIMAL-PSMA phase 2 trial for TLX597 recently completed enrolment to test specific dosing strategies directed toward earlier-stage patients.
This report was published on July 5, 2026.
Target price is $30.00 Current Price is $16.88 Difference: $13.12
If TLX meets the Canaccord Genuity target it will return approximately 78% (excluding dividends, fees and charges).
Current consensus price target is $26.10, suggesting upside of 51.6%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is -3.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Current consensus EPS estimate is 32.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 52.8.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: CNI - CENTURIA CAPITAL GROUP
For more info SHARE ANALYSIS: SUN - SUNCORP GROUP LIMITED
For more info SHARE ANALYSIS: TLS - TELSTRA GROUP LIMITED